🇬🇧 SEMAGLUTIDE in United Kingdom

NICE has issued 3 UK HTA decisions

Health technology assessment

3 decisions from NICE for SEMAGLUTIDE in United Kingdom.

NICE TA1152 — — Decision pending classification

• Indication assessed: reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity

NICE has recommended SEMAGLUTIDE for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity. This decision was made based on a commercial arrangement, indicating that the manufacturer has agreed to a specific price or reimbursement terms. There are no restrictions or conditions associated with this recommendation.

Read official decision →

NICE TA875 — ✓ Recommended

• Indication assessed: managing overweight and obesity

NICE recommended Semaglutide for managing overweight and obesity. This decision was made based on a commercial arrangement. No restriction or condition was placed on the use of Semaglutide.

Read official decision →

NICE TA910 — — Appraisal terminated

• Indication assessed: managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal)

NICE made a decision to terminate the appraisal of SEMAGLUTIDE for managing overweight and obesity in young people aged 12 to 17 years. This decision means that SEMAGLUTIDE will not be recommended for this specific indication. The cost basis of the decision is not reported.

Read official decision →

Frequently asked questions

Is SEMAGLUTIDE approved in United Kingdom?

SEMAGLUTIDE does not currently have UK marketing authorisation in our dataset.

Who is the marketing authorisation holder for SEMAGLUTIDE in United Kingdom?

Marketing authorisation holder not available in our data.

Has SEMAGLUTIDE been assessed by UK health technology agencies?

Yes — 3 UK HTA decisions on record from NICE.